iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Aurobindo Pharma Gets USFDA Nod for Generic Icatibant Injection, Launching Soon

17 Aug 2023 , 11:54 AM

Aurobindo Pharma’s subsidiary, Eugia Pharma Specialities, has received final approval from the USFDA for generic Icatibant injection used in treating hereditary angioedema. The approved injection is of strength 30 mg/3 mL (10 mg/mL) and comes in a single-dose pre-filled syringe.

The product is considered bioequivalent and therapeutically equivalent to Takeda Pharmaceuticals’ reference listed drug FIRAZYR. Aurobindo Pharma announced the product’s launch in September 2023. The approved product’s market size is estimated to be approximately USD 137 million based on IQVIA data for the 12 months ending June 2023.

For feedback and suggestions, write to us at editorial@iifl.com

explored-media

Related Tags

  • approval
  • Auro Pharma
  • Aurobindo Pharma
  • business
  • news
  • Pharma Stock
  • USFDA approval
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.